Navigation Links
Know Your G Spot
Date:12/17/2008

illing, and orgasms occur easier, more frequently, with less frustration, and are more intense.

"Fillers" often used to plump up other areas of the body, like the lips or wrinkles on the face, are used. The ideal filler would be safe, free of allergic potential, soft, easy to inject and last a long time. The current ideal filler is a group of products called hyaluronans, the most common of which are Perlane(R), Restylane(R) and Juvederm(TM). We know about the safety of these products as they have been used in other parts of the body in over 150,000,000 injections worldwide. Dr. Charles Mok has performed thousands of injections with these materials. For G spot enhancement, the filler is placed in the tissue of the G spot. By doing this, it thickens the tissue in this area, and projects it slightly into the vaginal canal where stimulation is much more intense.

The effects are immediate. This is a virtually painless procedure that takes about one minute. It will likely last for several months.

About Allure Medical Spa

Allure Medical Spa (http://www.AllureMedicalSpa.com) was not only one of the first Medical Spa facilities in Michigan but also in the United States. Allure Medical Spa is committed to providing the most innovative and safest technology available in the treatment of surgical and non-surgical cosmetic procedures. Professionalism and personal attention to detail has contributed to the success of tens of thousands of patients' cosmetic services countrywide. Our team of trained professionals delivers individualized solutions to ensure that you look and feel your best.


'/>"/>
SOURCE Allure Medical Spa
Copyright©2008 PR Newswire.
All rights reserved

6

GOOD

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 1H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 2H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 3Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 1Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 2PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 1PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 2